Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Jun 2025 value amounting to $88,000.

  • Ironwood Pharmaceuticals' Cash from Financing Activities rose 100.18% to $88,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$41.9 million, marking a year-over-year increase of 78.02%. This contributed to the annual value of -$107.0 million for FY2024, which is 138.60% down from last year.
  • According to the latest figures from Q2 2025, Ironwood Pharmaceuticals' Cash from Financing Activities is $88,000, which was up 1,366.67% from $6,000 recorded in Q1 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Financing Activities peaked at $399.1 million during Q2 2023, and registered a low of -$150.3 million during Q2 2022.
  • Its 3-year average for Cash from Financing Activities is $17.0 million, with a median of -$15.2 million in 2024.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Cash from Financing Activities surged by 820.00% in 2021, and later crashed by 9,508.78% in 2023.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Cash from Financing Activities stood at -$18.6 million in 2021, then skyrocketed by 115.10% to $2.8 million in 2022, then crashed by 1,914.11% to -$50.9 million in 2023, then soared by 70.75% to -$14.9 million in 2024, then skyrocketed by 100.18% to $88,000 in 2025.
  • Its Cash from Financing Activities stands at $88,000 for Q2 2025, versus $6,000 for Q1 2025 and -$14.9 million for Q4 2024.